About Magnus Biotech Private Limited
Data last updated: 06 January 2026
Magnus Biotech Private Limited is a private limited company based in Village Kunjpura, Haryana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 06 January 2003, the company has been in operation for over 23 years.
Registered with ROC Delhi under CIN U24231HR2003PTC035019.
Capital: an authorised share capital of ₹25 Lakh and a paid-up capital of ₹24.71 Lakh. It is led by directors including Manish Kumar and Lal Pratap Singh.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mugal Mazra Road P.O. Bada Gaon, Village Kunjpura, Haryana, India – 132023.
As per the financials filed for FY 2025, the company reported a revenue of ₹16.13 Cr, a growth of 5% compared to the previous year.
The company has a workforce of approximately 19 employees as per the latest available data.
The company is associated with 1 brand - Magnus Biotech. As per MCA filings, the company has open charges of ₹6.06 Cr and satisfied charges of ₹3 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website magnusbiotech.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressMugal Mazra Road P.O. Bada Gaon, Village Kunjpura, Haryana, India – 132023
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Magnus Biotech Private Limited
Magnus Biotech Private Limited operates one associated brand: Magnus Biotech. These brands represent Magnus Biotech Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures, supplies, and packages pharmaceutical products efficiently. | magnusbio.in |
Competitors & Alternatives of Magnus Biotech Private Limited
Brands and companies operating in the same space as Magnus Biotech Private Limited include Legacy Pharma Solutions, Natural Capsules, SCHOTT Poonawalla and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Legacy Pharma Solutions
|
Contract pharmaceutical packaging company | Earth City, United States, United States | 2003 |
Natural Capsules
|
Manufacturing and supply chain services for biopharma sector are provided. | Bengaluru, India, India | 1993 |
SCHOTT Poonawalla
|
Packaging solutions for pharmaceutical and biotech industries are provided. | Mumbai, India, India | 1990 |
Ideal Cures
|
Manufacturer of pharmaceutical excipients and coatings systems for solid oral dosage forms | Mumbai, India, India | 1999 |
Sanner
|
Plastic packaging solutions for pharmaceutical products are manufactured. | Bensheim, Germany, Germany | 1894 |
Cilicant
|
Drugs for the biopharma sector are manufactured and supplied. | Pune, India, India | 2011 |
Nutra-Med Packaging
|
Provider of drugs packaging services | Hanover, United States, United States | 1999 |
Eulysis
|
Diabetes management and lifestyle modification services are provided. | Cambridge, United States, United States | 2010 |
Business Activity of Magnus Biotech Private Limited
Magnus Biotech Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Magnus Biotech Private Limited
Magnus Biotech Private Limited is audited by PANKAJANEJAANDCO. for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| PANKAJANEJAANDCO. | blur-value | blur-value | blur-value |
Board of Directors of Magnus Biotech Private Limited
Magnus Biotech Private Limited is currently managed by 3 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manish Kumar | Director | 14 Aug 2023 | 2 Years 10 Months | Current |
| Lal Pratap Singh | Director | 27 Jul 2022 | 3 Years 11 Months | Current |
| Aman | Director | 27 Sep 2022 | 3 Years 9 Months | Current |
Financials of Magnus Biotech Private Limited FY 2025 filings available
Magnus Biotech Private Limited reported revenue of ₹16.13 Cr (up 5% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Magnus Biotech Private Limited
As of FY 2023, Magnus Biotech Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Magnus Biotech Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Feb 2022 | Hdfc Bank Limited | ₹4 Cr | Open |
| 24 Jul 2020 | Others | ₹2.06 Cr | Open |
| 07 Mar 2011 | State Bank of India | ₹30 Lakh | Satisfied |
| 04 Mar 2010 | State Bank of India | ₹2.1 Cr | Satisfied |
| 04 Mar 2010 | State Bank of India | ₹60 Lakh | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Magnus Biotech Private Limited
Magnus Biotech Private Limited has a workforce of 19 employees as of Apr 06, 2024.
Employee Count & EPFO Data of Magnus Biotech Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Magnus Biotech Private Limited
GSTIN & GST Filing Data of Magnus Biotech Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Magnus Biotech Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Magnus Biotech Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Magnus Biotech Private Limited
MSME Payment Delays by Magnus Biotech Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Magnus Biotech Private Limited
Subsidiaries & Group Companies of Magnus Biotech Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Magnus Biotech Private Limited with ownership details.
MCA Filings & Documents of Magnus Biotech Private Limited
MCA Filings & Documents of Magnus Biotech Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Magnus Biotech Private Limited
Frequently Asked Questions about Magnus Biotech Private Limited
Magnus Biotech Private Limited is an active private limited company in the pharma sector based in Village Kunjpura, Haryana, India. It was incorporated on 06 January 2003 (23+ years old) and is registered under CIN U24231HR2003PTC035019. The company has 19 employees.
Magnus Biotech Private Limited reported revenue of ₹16.13 Cr for FY 2025 (up 5.00% YoY).
The current directors of Magnus Biotech Private Limited are:
The primary industry of Magnus Biotech Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Magnus Biotech Private Limited can be reached at the registered office: Mugal Mazra Road P.O. Bada Gaon, Village Kunjpura, Haryana, India – 132023, or through the website magnusbiotech.in.
The authorised capital is ₹25 Lakh, and the paid-up capital is ₹24.71 Lakh.